EDAP TMS SA closed an underwritten public offering of 8,425,000 American Depositary Shares at $4.75 per ADS on August 14, 2026. The company subsequently exercised its over-allotment option in full on the same date, adding 1,263,750 additional ADSs to the offering. This issuance is expected to close on August 19, 2026, and generate approximately $5.6 million in net proceeds for the company after deducting underwriting discounts and commissions. EDAP TMS SA operates in the medical technology industry, specializing in minimally invasive treatments for prostate cancer.

EDAP TMS S.A. entered into an underwriting agreement for an underwritten public offering of 8,425,000 American Depositary Shares at $4.75 per ADS, generating approximately $37.1 million in net proceeds after discounts and expenses. The company granted underwriters a 30-day option to purchase up to an additional 1,263,750 ADSs. Proceeds will fund operating costs, capital expenditures, and general corporate purposes. Executive officers and directors agreed to 90-day lock-up restrictions on their shares. EDAP TMS S.A. operates in the medical technology industry, developing minimally invasive treatments for prostate cancer.

EDAP TMS S.A. reported second quarter 2026 financial results for its continuing HIFU operations, which generated $13.2 million in revenue, a 39% increase year-over-year. The company sold 13 Focal One systems and grew U.S. procedure volume by 47%. Gross margin improved to 55.6%, while operating expenses rose to $15.4 million due to rebranding costs. The net loss was $14.4 million, or ($0.38) per share, primarily driven by a $5.5 million warrant valuation impact. Cash and cash equivalents totaled $21.5 million. Management reiterated 2026 revenue guidance of $50.0 to $54.0 million. Additionally, the company announced an underwritten public offering for $40 million in gross proceeds expected to close on August 14, 2026. EDAP TMS S.A. operates in the medical device industry, developing and marketing minimally invasive robotic focal therapy systems.

FocalTherics (EDAP TMS SA) reported preliminary unaudited Q2 2026 financial results for its continuing HIFU operations, announcing revenue between $12.7 million and $13.2 million, a 34-39% increase year-over-year, with gross margins of 54-56%. The company classified its ESWL and Distribution segments as discontinued operations effective Q2 2026 due to a planned strategic exit. Cash, cash equivalents, and short-term investments totaled $21.5 million as of June 30, 2026. Additionally, the company highlighted commercial momentum with 13 Focal One system sales in the quarter and an installed base of 184 systems globally. The firm is advancing its robotic HIFU platform into new indications including benign prostatic hyperplasia (BPH) and deep infiltrating endometriosis, having initiated a limited commercial launch for endometriosis in Europe under its CE mark. EDAP TMS SA develops, manufactures, and markets minimally invasive medical devices worldwide to treat various conditions using proprietary focused ultrasound technology.

At its 2026 Annual General Meeting on June 26, 2026, EDAP TMS SA shareholders approved several key measures, including the renewal of director terms for Ryan Rhodes, Dr. Lance Willsey, Fran Schulz, Josh Levine, and David Horn. Shareholders approved amendments to the company's bylaws regarding share capital, the Board of Directors, and Shareholders' Meetings. Notably, the Board was granted broad authority to increase share capital through various issuance methods, including public offerings and specific categories of persons, and was authorized to execute merger-absorptions or spin-offs. A resolution to increase share capital for employees in company savings plans was not approved. The company operates in the environmental services industry, specializing in the treatment and recovery of industrial waste.